Massoud Walid, Paparel Philippe, Lopez Jean-Gabriel, Perrin Paul, Daumont Michele, Ruffion Alain
Department of Urology, Lyon-Sud Hospital, Lyon, France.
Int J Urol. 2006 Jan;13(1):87-8. doi: 10.1111/j.1442-2042.2006.01237.x.
We report the case of a T3 prostate cancer in a 70-year-old white man. Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer. Gonadotropin-releasing hormone agonists have been proven to have a double effect on androgen metabolism: an initially stimulating, followed by an inhibitory, effect on the pituitary gland. This phenomenon may be noxious in the case of gonadotroph adenoma, with subsequent symptoms of intracranial hypertension. Gonadotropin-releasing hormone antagonists (abarelix), by avoiding the flare-up reaction, might be used in such instances.
我们报告了一名70岁白人男性患T3期前列腺癌的病例。激素疗法是局部晚期和转移性前列腺癌治疗中的一个重要分支。促性腺激素释放激素激动剂已被证明对雄激素代谢有双重作用：最初对垂体有刺激作用，随后有抑制作用。在促性腺激素腺瘤的情况下，这种现象可能有害，随后会出现颅内高压症状。促性腺激素释放激素拮抗剂（阿巴瑞克）通过避免 flare-up 反应，可用于此类情况。
